CA3083343C - O-(5-amino-2-phenylbenzoxazol-7-yl)methyl-3,5-dichloro-l-tyrosine for use in treating cancer - Google Patents
O-(5-amino-2-phenylbenzoxazol-7-yl)methyl-3,5-dichloro-l-tyrosine for use in treating cancer Download PDFInfo
- Publication number
- CA3083343C CA3083343C CA3083343A CA3083343A CA3083343C CA 3083343 C CA3083343 C CA 3083343C CA 3083343 A CA3083343 A CA 3083343A CA 3083343 A CA3083343 A CA 3083343A CA 3083343 C CA3083343 C CA 3083343C
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- amino
- dichloro
- phenylbenzoxazol
- tyrosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017253385 | 2017-12-28 | ||
| JP2017-253385 | 2017-12-28 | ||
| PCT/JP2018/028887 WO2019130637A1 (ja) | 2017-12-28 | 2018-08-01 | がん治療薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3083343A1 CA3083343A1 (en) | 2019-07-04 |
| CA3083343C true CA3083343C (en) | 2022-04-26 |
Family
ID=67066788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3083343A Active CA3083343C (en) | 2017-12-28 | 2018-08-01 | O-(5-amino-2-phenylbenzoxazol-7-yl)methyl-3,5-dichloro-l-tyrosine for use in treating cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12458628B2 (https=) |
| EP (1) | EP3733175B1 (https=) |
| JP (4) | JP6546367B1 (https=) |
| KR (1) | KR102377742B1 (https=) |
| CN (1) | CN111491632A (https=) |
| BR (1) | BR112020012766A2 (https=) |
| CA (1) | CA3083343C (https=) |
| ES (1) | ES2960392T3 (https=) |
| MX (1) | MX2020006678A (https=) |
| WO (1) | WO2019130637A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11899019B2 (en) * | 2017-11-07 | 2024-02-13 | J-Pharma Co., Ltd. | Method for predicting efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, method for evaluating cancer grade, and method for enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy |
| PH12021552866A1 (en) | 2019-05-14 | 2022-11-07 | Tyme Inc | Compositions and methods for treating cancer |
| CN112336859A (zh) * | 2019-08-06 | 2021-02-09 | 上海绿谷制药有限公司 | 通过抑制t细胞摄取氨基酸治疗阿尔茨海默病的方法 |
| WO2021146506A2 (en) * | 2020-01-17 | 2021-07-22 | Tyme, Inc. | Compositions and methods for modulating cancer |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
| WO2022102687A1 (ja) * | 2020-11-11 | 2022-05-19 | ジェイファーマ株式会社 | がん治療剤 |
| TW202434224A (zh) | 2023-01-16 | 2024-09-01 | 日商Ｊ製藥股份有限公司 | 膽道癌治療劑 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2008081537A1 (ja) * | 2006-12-28 | 2010-04-30 | 株式会社ヒューマンセルシステムズ | Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体、それを含有するｌａｔ１阻害活性剤及びその製造方法 |
| JP6402393B2 (ja) * | 2014-05-15 | 2018-10-10 | ジェイファーマ株式会社 | 抗悪性腫瘍剤組成物 |
| JP2017155023A (ja) | 2016-03-04 | 2017-09-07 | ジェイファーマ株式会社 | Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体を含有する注射剤 |
| US11899019B2 (en) | 2017-11-07 | 2024-02-13 | J-Pharma Co., Ltd. | Method for predicting efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, method for evaluating cancer grade, and method for enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy |
| US20220288035A1 (en) | 2019-08-30 | 2022-09-15 | J-Pharma Co., Ltd. | A pharmaceutical composition for treating cancer used for a patient having specific genetic marker |
| WO2022102687A1 (ja) | 2020-11-11 | 2022-05-19 | ジェイファーマ株式会社 | がん治療剤 |
-
2018
- 2018-08-01 CN CN201880082290.5A patent/CN111491632A/zh active Pending
- 2018-08-01 EP EP18894766.7A patent/EP3733175B1/en active Active
- 2018-08-01 ES ES18894766T patent/ES2960392T3/es active Active
- 2018-08-01 CA CA3083343A patent/CA3083343C/en active Active
- 2018-08-01 US US16/957,293 patent/US12458628B2/en active Active
- 2018-08-01 JP JP2019503591A patent/JP6546367B1/ja active Active
- 2018-08-01 KR KR1020207021029A patent/KR102377742B1/ko active Active
- 2018-08-01 MX MX2020006678A patent/MX2020006678A/es unknown
- 2018-08-01 WO PCT/JP2018/028887 patent/WO2019130637A1/ja not_active Ceased
- 2018-08-01 BR BR112020012766-3A patent/BR112020012766A2/pt not_active Application Discontinuation
-
2019
- 2019-06-20 JP JP2019114783A patent/JP6734971B2/ja active Active
-
2020
- 2020-02-05 JP JP2020017875A patent/JP2020073586A/ja active Pending
-
2023
- 2023-05-31 JP JP2023089646A patent/JP7541400B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12458628B2 (en) | 2025-11-04 |
| KR102377742B1 (ko) | 2022-03-22 |
| JP6734971B2 (ja) | 2020-08-05 |
| CA3083343A1 (en) | 2019-07-04 |
| JP2019151672A (ja) | 2019-09-12 |
| BR112020012766A2 (pt) | 2020-12-01 |
| EP3733175B1 (en) | 2023-10-04 |
| ES2960392T3 (es) | 2024-03-04 |
| JPWO2019130637A1 (ja) | 2019-12-26 |
| KR20200101960A (ko) | 2020-08-28 |
| JP2023101705A (ja) | 2023-07-21 |
| EP3733175A1 (en) | 2020-11-04 |
| WO2019130637A1 (ja) | 2019-07-04 |
| MX2020006678A (es) | 2020-08-31 |
| CN111491632A (zh) | 2020-08-04 |
| JP2020073586A (ja) | 2020-05-14 |
| US20200405695A1 (en) | 2020-12-31 |
| JP6546367B1 (ja) | 2019-07-17 |
| JP7541400B2 (ja) | 2024-08-28 |
| EP3733175A4 (en) | 2021-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3083343C (en) | O-(5-amino-2-phenylbenzoxazol-7-yl)methyl-3,5-dichloro-l-tyrosine for use in treating cancer | |
| JP2019534330A (ja) | 亜鉛−γ−ＰＧＡ組成物およびがんを処置するための方法 | |
| US20210330626A1 (en) | Pharmaceutical composition for treating kidney cancer and application thereof | |
| TW202421112A (zh) | （－）－表沒食子兒茶素沒食子酸酯類化合物的應用 | |
| US11141421B2 (en) | Antitumor agent for biliary tract cancer and method for treating biliary tract cancer | |
| JP2025011312A (ja) | ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法 | |
| CN115400115B (zh) | 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途 | |
| CN116370642A (zh) | 含盐酸千金藤碱的药物联用物在前列腺癌治疗中的应用 | |
| US20210386862A1 (en) | Water-soluble macromolecular derivative of venetoclax | |
| CN112704665A (zh) | 替曲朵辛口服制剂、替曲朵辛冻干片及其应用 | |
| CN111939165A (zh) | 非天然人参皂苷3β-O-Glc-DM治疗脑瘤的用途 | |
| JP6801908B1 (ja) | ベネトクラクスの水溶性高分子誘導体 | |
| WO2020124495A1 (zh) | 含有亚铁氨基酸粒子的组合物及其用于制造治疗或改善胰脏相关疾病的医药品的用途 | |
| US8273721B2 (en) | Combination treatment for bladder cancer | |
| CN116966183A (zh) | 一种药物组合物及其在制备抗前列腺癌药物中的应用 | |
| CN119896741A (zh) | 一种靶向多发性骨髓瘤的纳米微球及其应用 | |
| CN121466049A (zh) | 沙美特罗和fasn抑制剂联用在制备治疗肺癌的药物中的应用 | |
| TWI619716B (zh) | 含維生素ｃ或其衍生物的替莫唑胺醫藥組成物及其製備方法 | |
| WO2018066278A1 (ja) | リンパ行性薬剤投与法で有効な薬剤 | |
| HK1185808B (en) | Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer | |
| HK1185808A1 (zh) | 用於治疗癌症的包含威罗菲尼和干扰素的组合疗法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200522 |